A Study of How CagriSema Works on Appetite in People With Excess Body Weight

NCT06267092 · Completed

Last updated 2026-05-28

This clinical trial is testing how the medication CagriSema affects appetite in adults who are overweight or have obesity.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 164 people

Who can join Ages 18–65 · all sexes

Timeline Started 2024-02 · est. completion 2025-12

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT06267092 ↗

Description as written by the study sponsor.

Part A: The study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake. Participants will not get any medicine and will be in a group that will be compared to another group receiving a weight-loss medicine. The study will last for about 6 months. Part B: The study will look at how CagriSema works on participants appetite and energy intake and will be compared with a ''dummy'' medicine. The study will also look at how participants brain works when participants take the medicine. Participants will either get CagriSema or ''dummy'' medicine.

Treatments tested

No treatment given Other

Participants will not get any medicine during this study.
Cagrilintide and Semaglutide Drug

Participants will receive subcutaneous (s.c.) injections of Cagrilintide and Semaglutide.
Placebo Drug

Participants will receive subcutaneous (s.c.) injections of placebo matched to Cagrilintide and Semaglutide.

Main thing measured	Change in mean postprandial appetite score based on visual analogue scale (VAS)
Sponsor	Novo Nordisk A/S
Conditions studied	Overweight, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06267092 ↗